Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On
18 months into the first serious clinical trials of CRISPR gene therapy for sickle cell disease and beta-thalassemia—and all patients […]
Learn more →







